News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
AstraZeneca also played a critical role in the global response to COVID-19.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
As per partnership, Carbanio will arrange raw materials and other custom chemicals for Proexp Pharma Pvt. Ltd. through an uninterrupted digital process of the company
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Subscribe To Our Newsletter & Stay Updated
